{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T12:33:20Z","timestamp":1742646800329},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpet.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T23:33:21Z","timestamp":1721259201000},"page":"515-524","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New PET Tracers for Symptomatic Myeloma"],"prefix":"10.1016","volume":"19","author":[{"given":"Sambit","family":"Sagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dikhra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanankulam Velliangiri","family":"Sivasankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2024.06.001_bib1","first-page":"461","article-title":"Multiple myeloma. Encycl","volume":"2","author":"Jurczyszyn","year":"2019","journal-title":"Biomed. Gerontol"},{"key":"10.1016\/j.cpet.2024.06.001_bib2","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am Fam Physician"},{"year":"2020","series-title":"Global cancer observatory: cancer today","author":"Ferlay","key":"10.1016\/j.cpet.2024.06.001_bib3"},{"issue":"11","key":"10.1016\/j.cpet.2024.06.001_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpet.2024.06.001_bib6","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8","key":"10.1016\/j.cpet.2024.06.001_bib7","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2024.06.001_bib8","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2024.06.001_bib9","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.06.001_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cpet.2024.06.001_bib11","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2024.06.001_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpet.2024.06.001_bib13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2024.06.001_bib14","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review","volume":"118","author":"Van Lammeren-Venema","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2024.06.001_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in Multiple Myeloma: a systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A\u00a0prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.cpet.2024.06.001_bib17","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.06.001_bib18","first-page":"469","article-title":"Comparison of (18)F-FDG PET\/CT and PET\/MRI in patients with multiple myeloma","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.06.001_bib19","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.cpet.2024.06.001_bib20","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.cpet.2024.06.001_bib21","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.3324\/haematol.2018.213041","article-title":"Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography\/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma","volume":"104","author":"Sachpekidis","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.cpet.2024.06.001_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpet.2024.06.001_bib23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.06.001_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/10428194.2018.1459602","article-title":"Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients","volume":"60","author":"Jamet","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.cpet.2024.06.001_bib25","first-page":"136","article-title":"Clinical significance of chemokine receptor (CCR1, CCR2, and CXCR4) expression in human myeloma cells: the association with disease activity and survival (vol 91, pg 200, 2006)","volume":"92","author":"Vande Broek","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.cpet.2024.06.001_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.06.001_bib27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.cpet.2024.06.001_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Hatano","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cpet.2024.06.001_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-021-03162-2","article-title":"Expression of activated integrin \u03b27 in multiple myeloma patients","volume":"114","author":"Hosen","year":"2021","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.cpet.2024.06.001_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64\u2013labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cpet.2024.06.001_bib31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1148\/radiol.2422051980","article-title":"Multiple myeloma: molecular imaging with 11 C-methionine PET\/CT\u2014initial experience","volume":"242","author":"Dankerl","year":"2007","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.cpet.2024.06.001_bib32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/cancers12041042","article-title":"18F-FDG and 11C-Methionine PET\/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers","volume":"12","author":"Morales-Lozano","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.cpet.2024.06.001_bib33","doi-asserted-by":"crossref","first-page":"e84840","DOI":"10.1371\/journal.pone.0084840","article-title":"Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology","volume":"8","author":"L\u00fcckerath","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2024.06.001_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2013.08.037","article-title":"Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid and L-[methyl-11C] methionine in human glioma cell lines","volume":"1535","author":"Ono","year":"2013","journal-title":"Brain Res"},{"issue":"8","key":"10.1016\/j.cpet.2024.06.001_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/RLU.0000000000002638","article-title":"Comparison of 11C-choline and 11C-methionine PET\/CT in multiple myeloma","volume":"44","author":"Lapa","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.06.001_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2024.06.001_bib38","first-page":"1592","article-title":"18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment","volume":"47","author":"Agool","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of 11 C-4\u2032-thiothymidine, 11 C-methionine, and 18 F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-018-0383-7","article-title":"Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18 F-FDG and 18 F-FLT PET\/CT imaging","volume":"8","author":"Sachpekidis","year":"2018","journal-title":"EJNMMI Res"},{"issue":"12","key":"10.1016\/j.cpet.2024.06.001_bib41","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.2967\/jnumed.110.077933","article-title":"Molecular mechanisms of bone 18F-NaF deposition","volume":"51","author":"Czernin","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.06.001_bib42","first-page":"151","article-title":"Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients","volume":"10","author":"Zadeh","year":"2020","journal-title":"American Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"7","key":"10.1016\/j.cpet.2024.06.001_bib43","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2024.06.001_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/RLU.0000000000000629","article-title":"18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?","volume":"40","author":"de Waal","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2024.06.001_bib45","unstructured":"Ulaner G, Sobol N, O'Donoghue J, et al. Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma."},{"key":"10.1016\/j.cpet.2024.06.001_bib46","first-page":"1","article-title":"Optimization of whole-body 2-[18 F] FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma","volume":"1","author":"Burns","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2024.06.001_bib47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00259-020-05049-6","article-title":"Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials","volume":"48","author":"Jamet","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.cpet.2024.06.001_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2021.280051","article-title":"Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study","volume":"108","author":"Kraeber-Bod\u00e9r\u00e9","year":"2023","journal-title":"Haematologica"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T22:04:51Z","timestamp":1724882691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1556859824000567"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.06.001","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New PET Tracers for Symptomatic Myeloma","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}